Horizon Therapeutics (HZNP) announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA candidate designed to treat gout by silencing liver xanthine dehydrogenase. The development of HZN-457 is part of a global collaboration and license agreement that the Company entered in 2021 with Arrowhead Pharmaceuticals (ARWR).
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- J&J says ‘it does not intent to make offer’ for Horizon Therapeutics
- J&J says won’t make offer for Horizon Therapeutics, Bloomberg reports
- Horizon Pharma put volume heavy and directionally bearish
- Sanofi says any offer for Horizon Therapeutics, if made, to be ‘solely in cash’
